SWSuryo Anggoro Kusumo Wibowo

Suryo Anggoro Kusumo Wibowo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suryo Anggoro Kusumo Wibowo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and factors associated with cognitive impairment in rheumatoid arthritis patients: a cross-sectional study

    by Rudy Hidayat, Dian Azzahra, Suryo Anggoro Kusumo Wibowo, Anna Ariane, Faisal Parlindungan, Johanda Damanik, Abirianty Priandani Araminta, Fara Fauzia, Jessica Audrey

    Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease which has been associated with an increased risk of cognitive impairment. The objective of this study was to determine the pre­valence and possible predictors of cognitive impairment in a cohort of RA individuals. Material and methods: A cross-sectional study was conducted among RA patients aged ≥ 18 years visiting our rheumatology clinic. Demographic, clinical, and laboratory data were collected. Cognitive function was assessed using the Montreal Cognitive Assessment-Indonesian (MoCA-INA) questionnaire. The subjects were classified as cognitively impaired if they scored less than 26. Bivariate and multivariate logistic regression analyses were performed to identify predictive factors of cognitive impairment. Results: A total of 204 participants were included in the analysis, with a mean age of 48.60 (SD ±12.19) years. The prevalence of cognitive impairment based on MoCA-INA scores was 54.9%, with an overall median MoCA-INA score of 25 (range: 3–30). Subjects in the cognitively impaired group scored significantly lower in nearly all the MoCA domains: visuospatial/executive, naming, attention, delayed recall, abstraction, and language. Based on the multivariate analysis, it was found that older age (OR = 1.045, 95% CI: 1.018–1.073, p = 0.001), low education level (OR = 2.260, 95% CI: 1.153–4.432, p = 0.018), intermediate education level (OR = 3.161, 95% CI: 1.359–7.353, p = 0.008) education level, and glucocorticosteroid (GC) use (OR = 2.147, 95% CI: 1.133–4.070, p = 0.019) were significant predictors of cognitive impairment in this study. Conclusions: Cognitive impairment was identified in 54.9% of RA patients in this study. Older age, lower education levels, and GC use were significantly associated with increased risk of cognitive impairment.

  • Open Access

    Association of Beta-2 Microglobulin Concentrations with Frailty in Patients Undergoing Chronic Hemodialysis

    by Pringgodigdo Nugroho, Nur Hidayat, Kuntjoro Harimurti, Ikhwan Rinaldi, Eric Daniel Tenda, Andhika Rachman, Suryo Anggoro Kusumo Wibowo

    Introduction: Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited. Purpose: To determine the relationship between B2M concentration and frailty in hemodialysis patients. Patients and Methods: This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty. Results: A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8– 36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69– 33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88– 10.04) was strongly and consistently associated with frailty prevalence. Conclusion: Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.


  • Open Access

    Frequency and factors associated with loss to follow-up in newly diagnosed rheumatoid arthritis patient: a single-centre study

    by Sumariyono Sumariyono, Rudy Hidayat, Faisal Parlindungan, Suryo Anggoro Kusumo Wibowo, Anna Ariane, Johanda Damanik, Abirianty Priandani Araminta, Ryzkianty Annis Nurdin

    Introduction: Lost to follow-up (LTFU) rheumatoid arthritis (RA) patients constitute a population that potentially experiences worsening of their disease. This study aimed to determine the frequency of LTFU and the possible associated factors in newly diagnosed RA patients in our outpatient clinic.Material and methods: A retrospective cohort study was conducted using 260 newly diagnosed RA patients. Those who did not attend their scheduled appointment for more than 3 months were defined as LTFU. We used a Likert scale questionnaire to explore the perception and the possible reasons for LTFU by phone. Bivariate and multivariate logistic regression analyses were performed to explore the factors associated with LTFU.Results: There were 65 patients (25%) who were LTFU. We contacted 34 of them and selected 34 age-matched routinely followed-up (RFU) patients as controls. The reasons for LTFU were distance from house to hospital constraints (76%), busy (56%), transportation constraints (38%), dissatisfaction with the outpatient clinic service (21%), lack of information about their disease (18%), having other comorbidities that compelled them to go to another department’s clinic (15%), difficulties understanding the clinic registration flow system (9%), and having minimal symptoms (6%). Using the c2 test, we found that transportation constraints and busyness were significantly different between LTFU and routinely followed up patients (p-value 0.008 and 0.200, respectively). After multivariate analysis, transportation constraints remained a significant factor (OR = 6.397; 05% CI: 1.622–25.228).Conclusions: Among newly diagnosed RA patients, 65 (25%) were LTFU. Transportation constraints and busyness were factors associated with LTFU. Further multivariate analysis showed that the factor transportation constraints was significantly associated with LTFU of RA patients in this study.


  • Open Access

    COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

    by Leonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, Jessica Day, Parikshit Sen, Jucier Gonçalves Junior, James B. Lilleker, Mrudula Joshi, Vishwesh Agarwal, Sinan Kardes, et al.

    Objectives: We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods: This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results: Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions: Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs.


  • Open Access

    Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity

    by Tulus Widiyanto, Rudy Hidayat, R.M. Suryo Anggoro Kusumo Wibowo, Hamzah Shatri

    Introduction: Rheumatoid arthritis is associated with bone loss and the risk of osteoporotic fracture. Bone loss in this disease is mediated by inflammation and autoimmunity. Many studies have shown that anti-citrullinated protein antibody is capable of inducing bone loss through several mechanisms. This study aimed to determine the relationship between autoimmunity, represented by anti-mutated citrullinated vimentin (anti-MCV) in this study, and bone loss, represented by C-terminal cross-linking telopeptide of type I collagen (CTX-1), and N-terminal pro-peptide of type 1 procollagen (P1NP) in this study, in patients with rheumatoid arthritis in remission and low disease activity.Material and methods: This study enrolled 38 rheumatoid arthritis patients with disease remission and low disease activity in Cipto Mangunkusumo Hospital between August and September 2019. We collected the patients’ demographic data, Disease Activity Score 28 (DAS28), and treatment history. All participants underwent blood work for anti-MCV, CTX-1, and P1NP.Results: Thirty-four of the subjects were women (89.5%), with the mean age of 40 ±7.6 years and the median disease duration of 36 months. Among the subjects, 26 patients (68.4%) were anti-MCV positive. There was no correlation between anti-MCV and CTX-1 levels (r = 0.101, p = 0.274). There was a moderate negative correlation between anti-MCV and P1NP (r = –0.449, p = 0.001). The mean difference of P1NP according to anti-MCV level also showed a significant difference (p = 0.019).Conclusions: The anti-MCV levels are not directly correlated with CTX-1 levels, indicating heterogeneity in the disease course even after inflammation has ceased. The anti-MCV and P1NP levels are moderately correlated, indicating that bone formation is resumed during the suppression of autoimmunity.